<style>
    #aspirin_section {
        width: 1000px;
        margin:20px auto;
        padding: 0 10px;
        line-height: 22px;
        font-size: 14px;
    }

    #aspirin_section h1{
        font-size: 30px;
        font-weight: bold;
        line-height: 28px;
        text-align: center;
    }

    #aspirin_section h2{
        font-size: 18px;
        font-weight: bold;
        text-align: center;
    }
    #aspirin_section h3{
        font-size: 16px;
        font-weight: bold;
    }

</style>

<section id="aspirin_section">
    <div class="breadcrumbs_container">
        <nav>
            <ul class="breadcrumb" xmlns:v="http://rdf.data-vocabulary.org/#">
                <li typeof="v:Breadcrumb">
                    <a rel="v:url" property="v:title" href="<?php echo base_url(); ?>">Home</a>
                    <span>»</span>
                </li>
                <li typeof="v:Breadcrumb">
                    <a rel="v:url" property="v:title" href="<?php echo base_url(); ?>cardiovascular-genetics">Cardiovascular-Genetics</a>
                    <span>»</span>
                </li>
                <li typeof="v:Breadcrumb">
                    <a class="active" property="v:title">LPA_Aspirin</a>
                </li>
            </ul>
        </nav>
    </div>


    <h1>
        LPA-Aspirin Genotype Test
    </h1>
    <br>
    <h2>
        Helping predict risk of a Cardiovascular Disease (CVD)

        event and response to aspirin therapy
    </h2>
    <br>

    <hr>
    <h3>Carriers of the LPA-Aspirin genotype have been reported to have:</h3>

    <br>

    <ul class="normal_ul_list">
        <li>
            Higher risk of CVD events compared with non carriers. This risk is independent of and similar in magnitude to

            traditional risk factors.
        </li>
        <li>
            Reduced risk of primary CVD events with aspirin therapy; this risk reduction was not observed in non carriers.
        </li>
    </ul>

    <br>


    <h3>
        The following distinctions were reported between LPA 4399Met carriers and non carriers 

        in multiple research studies for CVD risk and in one study for response to aspirin therapy:
    </h3>

    <br>
    
    <style>
        table{
            text-align: center;
        }
        thead{
            color: dodgerblue;
            font-weight: bold;
            
        }
        tr, td{
            border: 1px solid #ccc;
        }
        
    </style>

    <table>
        <thead>
            <tr>
                <td style="width: 300px;">LPA-Aspirin</td>
                <td colspan="2">Carriers</td>
                <td style="width: 300px;">Non-carriers</td>
            </tr>
        </thead>
        <tbody>
            <tr>
                <td>Genotype</td>
                <td style="background-color: crimson; color:white;">Met/Met</td>
                <td style="background-color: crimson; color:white;">lle/Met</td>
                <td style="background-color: #49a430; color:white;">lle/lle</td>
            </tr>
            <tr>
                <td>CVD Risk Reduction with Aspirin Therapy</td>
                <td colspan="2">56% relative risk reduction</td>
                <td>No significant risk reduction</td>
            </tr>
            <tr>
                <td>CVD Event Risk</td>
                <td colspan="2">Two-fold increased risk</td>
                <td>No increased risk</td>
            </tr>
            <tr>
                <td>Number Needed to Treat (NNT) with Aspirin to Prevent 1 CVD Event</td>
                <td colspan="2">37</td>
                <td>625</td>
            </tr>

        </tbody>

    </table>


</section>